Anti-Rheumatic Drugs - Spain

Spain

The Anti-Rheumatic Drugs market in Spain is expected to witness a significant growth in revenue, reaching a projected value of €0.34bn by 2024.
This growth is anticipated to continue at a steady pace, with an annual growth rate (CAGR 2024-2029) of 0.00%.
As a result, the market volume is estimated to reach €0.34bn by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue in the Anti-Rheumatic Drugs market, with a staggering €31,850.00m in 2024.
In Spain, there is a growing demand for innovative anti-rheumatic drugs to address the increasing prevalence of rheumatoid arthritis among the aging population.

Key regions: Germany, United States, India, Japan, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The Anti-Rheumatic Drugs market in Spain has been experiencing a steady growth in recent years.

Customer preferences: The demand for Anti-Rheumatic Drugs in Spain is driven by the increasing prevalence of rheumatoid arthritis and osteoarthritis amongst the aging population. Patients are also showing a preference for biologic drugs due to their effectiveness in treating the disease and minimal side-effects. Furthermore, the availability of generic drugs at a lower cost is also a factor contributing to the growth of the market.

Trends in the market: The Anti-Rheumatic Drugs market in Spain is witnessing an increase in the number of biologic drugs being prescribed. The use of biologic drugs has increased due to their effectiveness in reducing inflammation and slowing the progression of the disease. The market is also seeing a trend towards combination therapy, where biologic drugs are used in combination with non-biologic drugs to achieve better outcomes. The market is expected to continue to grow as new biologic drugs are introduced into the market.

Local special circumstances: Spain has a high prevalence of rheumatoid arthritis and osteoarthritis amongst the aging population. The Spanish government has implemented policies to improve access to healthcare services, which has resulted in an increase in the number of patients seeking treatment for these conditions. The government has also introduced measures to reduce the cost of drugs, which has made it more affordable for patients to access treatment.

Underlying macroeconomic factors: Spain has a stable economy with a well-developed healthcare system. The country has a universal healthcare system that provides free or low-cost healthcare services to all citizens. The government has also implemented policies to improve access to healthcare services in rural areas. The aging population in Spain is also contributing to the growth of the market, as the prevalence of rheumatoid arthritis and osteoarthritis increases with age. The availability of generic drugs at a lower cost is also a factor contributing to the growth of the market.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.